Applied Filters
BIO preview: a meeting of minds
More than 15,000 life sciences industry professionals will arrive in San Diego this month for the annual BIO International Convention. LSIPR looks at some of the most interesting sessions, and talks to a couple of speakers.
IP in Mexico: alternative remedies
Acting against infringers can involve the pharmaceutical regulatory framework and civil law as well as following the more usual pathways, says José R. Trigueros.
New labelling requirements in Mexico
Amended rules for food and drink packaging seek to ensure that people can easily identify the high calorific content of some of these products, as Daniel Sanchez and Victor Ramirez report.
Patent protection of amino acid and nucleic acid sequences
The rate of development in the biotech sector means revisions to the patent guidelines are more needed than ever, says Marisa Moura Momoli.
Biotechnology drugs: threats and opportunities
The patent regulatory framework in Mexico needs to evolve if the investment in, and marketing of, promising biotechnology drug products is to succeed, says Hector E. Chagoya.
Double patenting: expiry dates hold the key
Obviousness-type double patenting is a serious consideration that patent owners should keep in mind during the examination of an application or in performing due diligence on a patent portfolio, says MaryAnne Armstrong.
Patent term: proceed with caution
The effect of obviousness-type double patenting on patent term extension and patent term adjustment in the biotech and pharma industry needs careful consideration, as Gaby L. Longsworth and Eric K. Steffe report.
Subject matter eligibility: interpreting the USPTO guidelines
The new examination guidelines do not carry the weight of law, and it is not likely that their more extreme aspects will withstand judicial scrutiny, but practitioners need to keep tabs on court decisions, says Courtenay C. Brinckerhoff.
Dolly the sheep: the demise of biotechnology patents
With the Federal Circuit relying on the precedent set by the Prometheus and Myriad decisions, Dolly the sheep has been summarily declared ineligible for patent protection. Nabeela Rasheed sums up the implications.
Protecting biomarkers and personalised/stratified medicine
With careful patent drafting and prosecution, it is possible to capture significant IP value in the clinically—and commercially—important area of biomarkers, says Stephanie Pilkington of Potter Clarkson.
